Clasp Therapeutics Launches with $150 Million to Pioneer Precision Immuno-Oncology Using Next-Generation T Cell Engagers with Unparalleled Specificity

GO BACK TO PRESS RELEASES & MEDIA Press Release March 20, 2024 Clasp Therapeutics Launches with $150 Million to Pioneer Precision Immuno-Oncology Using Next-Generation T Cell Engagers with Unparalleled Specificity Series A financing led by Catalio Capital Management, Third Rock Ventures and Novo Holdings Platform enables modular T cell engagers tailored to oncogenic driver mutations for highly specific tumor targeting Founders include cancer genetics pioneer Bert Vogelstein, M.D., and immuno-oncology innovator Drew Pardoll, M.D., Ph.D., both of Johns Hopkins University CAMBRIDGE , Mass. and RO